AFTER-ACCREDITATION PROMOTION

INTERIM GUIDELINES FOR THE USE OF AND SAFETY MONITORING OF BEDAQUILINE (SIRTUROTM) FOR THE TREATMENT OF PULMONARY MULTIDRUG-RESISTANT TUBERCULOSIS

WB2329

FACULTY/CREDENTIALS:
Kenneth G. Castro, MD, Director, Director, Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
Terence L Chorba, MD, DSc, MPH, MPA, FACP, FIDSA, Chief, Field Services and Evaluation Branch, Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
Phillip LoBue, MD, Associate Director for Science, Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
Sundari R Mase, MD, MPH, Chief, Medical Team, Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

DATE: **October 25, 2013**

ORIGINATION/EXPIRATION DATES: **October 25, 2013 - October 25, 2015**

LOCATION: ***MMWR* Journal** http://www.cdc.gov/mmwr

HARDWARE/SOFTWARE: Computer-Internet;

MATERIALS: Access to computer

TARGET AUDIENCE: Physicians, Registered Nurses, Laboratorians, Medical Assistants, Physician Assistants, Public Health Professionals, Health care workers, health educators

PREREQUISITES: Knowledge of Pulmonary Multidrug-Resistant Tuberculosis

PROGRAM DESCRIPTION: The goal of this report is to provide guidance for the use of bedaquiline fumarate, a newly approved MDR TB drug for the treatment of Pulmonary Multidrug-Resistant Tuberculosis**.**

OBJECTIVES:
1. describe the basic mechanism of action of bedaquiline
2. describe the basic epidemiology of MDR TB
3. describe the way in which drug-resistant TB develops

4. describe the rationale and methods employed by CDC to develop new recommendations
5. describe the efficacy and safety data that led to the accelerated approval of bedaquiline by the FDA
6. describe the patients in whom bedaquiline may be considered
7. describe the dosing, administration, precautions and safety monitoring recommended for patients receiving bedaquiline

CONTACT INFORMATION: Office of Sundari Mase, (404) 639-5336

ACCREDITATION STATEMENTS:

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

The Centers for Disease Control and Prevention designates this **<enduring activity >** for a maximum of 1.75 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity provides _1.7__ contact hours.

CEU: The CDC has been approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 22102. The CDC is authorized by IACET to offer _0.2__ ANSI/IACET CEU's for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designed for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to _2__ Category I continuing education contact hours. Maximum advanced level continuing education contact hours available is _0__ CDC provider number **GA0082**

DISCLOSURE: In compliance with continuing education requirements, all planners, presenters, and their spouses/partners must disclose any financial or other associations with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters as well as any use of unlabeled product(s) or product(s) under investigational use.

CDC, our planners, our content experts and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias.

Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Kenneth Castro, Terence Chorba, Phillip LoBue and Sundari Mase's discussion of Bedaquiline. They will be discussing the approval of Bedaquiline, but its use for extrapulmonary and pediatric TB is off label.

CDC does not accept commercial support.

SUPPORT/FUNDING: CDC

FEES: No fees are charged for CDC's CE activities.

METHOD OF PARTICIPATION:
You may participate in the educational activity by viewing the program information above.

To evaluate this educational activity, receive a certificate/statement of credit, to print-out an on-going transcript of all your TCEOnline CE activities for credits/contact hours, please go to: www.cdc.gov/TCEOnline.

FEES: No fees are charged for CDC's CE activities.